Shun-Ichi Watanabe
Overview
Explore the profile of Shun-Ichi Watanabe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
264
Citations
5523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, et al.
Lung Cancer
. 2025 Mar;
202:108494.
PMID: 40088580
Background: In EGFR-mutated lung adenocarcinoma (EGFRm LUAD), EGFR mutations do not necessarily result in increased EGFR expression (EGFR-exp), which differs among patients. However, the factors influencing EGFR-exp and the impact...
2.
Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, et al.
Lung Cancer
. 2025 Feb;
200:108102.
PMID: 39924255
Introduction: Data on chemotherapy for elderly, poor performance status (PS) non-small cell lung cancer (NSCLC) are clinically important but insufficient due to their exclusion from most interventional studies. This study...
3.
Nakagawa K, Watanabe S, Wakabayashi M, Sekino Y
J Thorac Oncol
. 2025 Feb;
20(2):e27-e28.
PMID: 39914927
No abstract available.
4.
Nakagawa K, Watanabe S, Wakabayashi M, Sekino Y
J Thorac Oncol
. 2025 Feb;
20(2):e24-e25.
PMID: 39914925
No abstract available.
5.
Nakagawa K, Watanabe S, Wakabayashi M, Sekino Y
J Thorac Oncol
. 2025 Feb;
20(2):e22-e23.
PMID: 39914923
No abstract available.
6.
Kosuge A, Yoshida Y, Yotsukura M, Watanabe S
Jpn J Clin Oncol
. 2025 Feb;
55(2):194-197.
PMID: 39902921
Background: The optimal surgical procedure for tumors extending deep into the lung parenchyma of the opposite lobe beyond the fissure remains controversial. The current study aimed to examine whether en...
7.
Masuda K, Yoshida T, Motoi N, Shinno Y, Matsumoto Y, Okuma Y, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15529.
PMID: 39809728
Background: Schlafen 11 (SLFN-11) has been identified as a sensitizer of tumor cells to DNA-damaging agents. However, the relationship between SLFN-11 expression and clinical outcomes in patients with small cell...
8.
Yotsukura M, Yoshida Y, Nakagawa K, Watanabe S
Ann Thorac Surg Short Rep
. 2025 Jan;
2(4):597-602.
PMID: 39790586
Background: In malignant pleural mesothelioma), it is difficult to evaluate the degree of tumor progression using imaging findings. It is essential to develop an objective index that is independent of...
9.
Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, et al.
Cancer Lett
. 2024 Dec;
611:217414.
PMID: 39725152
KRAS inhibitors sotorasib and adagrasib have been approved for the treatment of KRAS-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple...
10.
Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe S, et al.
Sci Rep
. 2024 Dec;
14(1):30457.
PMID: 39672904
No abstract available.